Results 191 to 200 of about 30,107 (256)

Status of oncology drugs with a conditional approval: A cross‐sectional comparison of the Food and Drug Administration and Health Canada

British Journal of Clinical Pharmacology, EarlyView.
Aims This study looks at the status of the same drugs conditionally approved by the Food and Drug Administration and Health Canada for the same oncology indication. Methods Lists of oncology drugs with a conditional approval from the Food and Drug Administration and Health Canada were generated and drug pairs with the same indication were matched ...
Joel Lexchin
wiley   +1 more source

Adverse Outcomes in Patients on Chronic Anticoagulation Therapy Undergoing Sleeve Gastrectomy Conversions: Analysis of 30,664 Patients from the MBSAQIP Database. [PDF]

Obes Surg
Barajas-Gamboa JS, Restrepo-Rodas G, Mocanu V, Wills MV, Shin TH, Kachornvitaya P, Romero-Velez G, Zhu X, Strong AT, Navarrete S, Corcelles R, Guerron AD, Rodriguez J, Kroh M, Dang JT.   +14 more
europepmc   +1 more source

Trends in the utilization, expenditure and costs of noninsulin glucose‐lowering drugs in the Medicaid population: Steady increases in glucagon‐like peptide‐1 receptor agonist and sodium–glucose transporter‐2 inhibitor use, prices and expenditure

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to analyse changes in the utilization, expenditure and average cost of noninsulin glucose‐lowering drugs (GLDs) between 2008 and 2023. Methods This was a retrospective observational study of 2008–2023 data from the National Medicaid State Drug Utilization database.
Rawan O. Almadfaa
wiley   +1 more source

P439: TACSTD2-related gelatinous drop-like corneal dystrophy: An asymmetrical exception

Genetics in Medicine Open
Rebecca Procopio, Tatyana Milman, Adele Schneider, Beeran Meghpara   +3 more
doaj   +1 more source

Re: McCarthy et al: A Practical Guide to Evaluating Artificial Intelligence Imaging Models in Scientific Literature. [PDF]

Ophthalmol Sci
Bair H.
europepmc   +1 more source

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

British Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló, Attila Imre, Gábor Varga, Sándor Kovács, György Tímár, Balázs Nagy   +5 more
wiley   +1 more source

Air pollution, driver mutations, and survival in non-small cell lung cancer: insights from a high-altitude Hispanic cohort. [PDF]

Transl Lung Cancer Res
Tamayo M, Duque-Clavijo N, Herrera-López AB, Estrada-Schweineberg M, Bejarano AF, Pardo-Aljure J, Baldovino-Chiquillo L, Uscategui-López D, Dueñas-Hernández S, Molina MP, García MJ, Cañon D, Baldión M, Cruz S, Pino LE, Vargas H, Segovia J, Cantor E, Valencia-Estupiñan O, Sarmiento OL, Cardona AF, Wills B.   +21 more
europepmc   +1 more source

Do drugs approved via expedited approval pathways have therapeutic advantages? A systematic review and meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Regulators use expedited approval pathways to speed market approval and patient access to promising new drugs. However, there is uncertainty about whether these pathways are successful in approving drugs with significant therapeutic advantages. This systematic review aims to examine the safety, effectiveness and cost‐effectiveness of drugs approved via
Ashleigh Hooimeyer, Eliza J. McEwin, Zhicheng Wang, Joel Lexchin, Barbara Mintzes   +4 more
wiley   +1 more source

Effect of a digital dietary intervention on diet quality in young adults in Norway - The PREPARED randomised controlled trial. [PDF]

BMC Nutr
Valen EN, Wills AK, Medin AC, Vik FN, Engeset D, Salvesen L, Hillesund ER, Øverby NC.   +7 more
europepmc   +1 more source

Practice, knowledge and attitude of physicians and pharmacists towards the spontaneous reporting system of adverse drug reactions in Switzerland

British Journal of Clinical Pharmacology, EarlyView.
Introduction Introduction Reporting adverse drug reactions (ADRs) is essential for detecting drug risks. Despite legal obligations in Switzerland, underreporting remains an issue. This study assessed practice, knowledge and attitudes towards the spontaneous ADR reporting system among physicians and pharmacists.
Fiona A. Strobel, Thomas Stammschulte, Patrick E. Beeler   +2 more
wiley   +1 more source